Plus Therapeutics, Inc. announced on February 18, 2025, the closing of a financing round totaling $5.7 million. This capital infusion is intended to support the company's leptomeningeal metastases (LM) program.
The financing included a $3.7 million private placement from existing investors. Additionally, the company received a $2.0 million funding advance from the Cancer Prevention and Research Institute of Texas (CPRIT).
This combination of dilutive and non-dilutive funding strengthens the company's financial position. It enables the continued clinical development of its targeted radiotherapeutics for CNS cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.